Navigation Links
Merrimack to Present New Analyses of Phase 3 NAPOLI-1 Data at the ESMO 18th World Congress on Gastrointestinal Cancer
Date:6/21/2016

CAMBRIDGE, Mass., June 21, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that it will present new analyses of the Phase 3 NAPOLI-1 data in an oral presentation and poster discussion session at the European Society for Medical Oncology  (ESMO) 18th World Congress on Gastrointestinal Cancer, June 29 – July 2, 2016 in Barcelona, Spain. An oral presentation by Dr. Richard Hubner, Consultant Medical Oncologist, The Christie NHS Foundation Trust and investigator on the NAPOLI-1 trial, will compare the effects of ONIVYDE® (also known as "nal-IRI") in combination with fluorouracil and leucovorin on quality of life in patients with metastatic pancreatic adenocarcinoma previously treated with gemcitabine-based therapy versus treatment with fluorouracil and leucovorin alone.

Merrimack will also present an analysis of the NAPOLI-1 safety data across patient subgroups in a poster discussion session and a trials-in-progress poster on a Phase 2 study evaluating ONIVYDE containing regimens as first-line therapy for patients with metastatic pancreatic cancer.

Oral Presentation:

  • Effects of nal-IRI (MM-398) ± 5-fluorouracil on quality of life (QoL) in NAPOLI-1: A phase 3 study in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy (Abstract O-004)
    Wednesday, June 29, 2016, 5:53 - 6:03 PM CEST
    Session: Pancreatic Cancer
    Poster Presentation Time: Thursday, June 30, 2016, 11:00 - 11:30 AM and 5:10 - 5:40 PM CEST
    CCIB, Exhibit Hall

Poster Sessions:

  • Safety across subgroups in NAPOLI-1: A phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy (Abstract PD-023)
    Session: Pancreatic Cancer
    Poster Discussion Time: Thursday, June 30, 2016, 11:00 - 11:30 AM CEST
    Poster Presentation Time: Thursday, June 30, 2016, 11:00 - 11:30 AM and 5:10 - 5:40 PM CEST
    CCIB, Exhibit Hall
  • Nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine as first-line therapy in patients with metastatic pancreatic adenocarcinoma (mPAC): A randomized, open-label phase 2 study (Abstract P-287)
    Session: Pancreatic Cancer
    Poster Presentation Time: Thursday, June 30, 2016, 11:00 - 11:30 AM and 5:10 - 5:40 PM CEST
    CCIB, Exhibit Hall

About Merrimack

Merrimack is a fully integrated biopharmaceutical company that views cancer as a complex engineering challenge. Through systems biology, which brings together the fields of biology, computing and engineering, Merrimack aims to decrease uncertainty in drug development and clinical validation, and move discovery efforts beyond trial and error. Such an approach has the potential to make individualized treatment of patients a reality. Merrimack's first commercial product, ONIVYDE® (irinotecan liposome injection), was approved by the U.S. FDA in October 2015. With four additional candidates in clinical studies, several in preclinical development and multiple biomarkers designed to support patient selection, Merrimack is building one of the most robust oncology pipelines in the industry. For more information, please visit Merrimack's website at www.merrimack.com or connect on Twitter at @MerrimackPharma.

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.

Contacts:
Media Contact
Marianne McMorrow
774-776-1478
mmcmorrow@merrimack.com

Investor Contact
Geoffrey Grande, CFA
617-441-7602
ggrande@merrimack.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/merrimack-to-present-new-analyses-of-phase-3-napoli-1-data-at-the-esmo-18th-world-congress-on-gastrointestinal-cancer-300288223.html


'/>"/>
SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Merrimack Reports Fourth Quarter 2015 Financial Results
2. Merrimack Announces Private Placement of $175 Million of Senior Secured Notes
3. Merrimack Amends MM-121 Phase 2 Clinical Study in Heregulin-Positive Non-Small Cell Lung Cancer to Support Potential Registration
4. Merrimack Reports Third Quarter 2015 Financial Results
5. Merrimack to Present Research on Multiple Programs at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Merrimack Announces Timing of Third Quarter 2015 Investor Conference Call
7. PharmaEngine Announces U.S. FDA Approves Merrimacks ONIVYDE(TM) (irinotecan liposome injection)
8. Merrimack Pharmaceuticals Names Dr. Yasir Al-Wakeel as Chief Financial Officer and Head of Corporate Development
9. Merrimack Pharmaceuticals Announces Timing of Second Quarter 2015 Investor Conference Call
10. Merrimack Pharmaceuticals Announces the Addition of John M. Dineen, Former CEO of GE Healthcare, to Its Board of Directors
11. Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... R.I. , Sept. 25, 2017  EpiVax, ... assessment, vaccine design, and immune-engineering today announced the ... on the development of personalized therapeutic cancer vaccines. ... has provided exclusive access to enabling technologies to ... Eng., MBA will lead EpiVax Oncology as Chief ...
(Date:9/22/2017)... , Sept. 22, 2017 AVACEN Medical ... device is now successfully helping those with the widespread ... Fibromyalgia diagnosed Amanda in Essex, England ... and washing my hair, experiencing no sleep at all, ... painful spasm… I cannot recommend [the AVACEN 100] enough, ...
(Date:9/18/2017)... KALAMAZOO, Mich. , Sept. 18, 2017 /PRNewswire/ ... and OptiMed Specialty Pharmacy of Kalamazoo, Mich. ... a strategic hub service that expedites and streamlines patient ... spirometer, Spiro PD 2.0, and wellness management services.  ... a medical device used to measure lung function for ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... While it’s often important ... problem. Fortunately, an inventor from Austin, Texas, has identified a solution. , She developed ... darkness or restricted lighting. As such, it eliminates the need to turn on a ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, ... guideline updates for the primary prevention of cardiovascular diseases during the 15th ...
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of ... collection of specialty vendors and unique items from across the nation, this holiday-themed event ... wellness services offered by the VNA. The boutique will be open Saturday, November ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor ... on sciatica in a new episode of "Success Files," which is an award-winning ... innovation and investigates each subject in-depth with passion and integrity. , Sciatica occurs ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare ... program management, will showcase a range of technology and learning solutions at the ... Convention and Expo to be held October 14–18, 2017 at the Mandalay Bay ...
Breaking Medicine News(10 mins):